Full Year 2024 Australian Clinical Labs Ltd Earnings Call Transcript
Key Points
- Australian Clinical Labs Ltd (ASX:ACL) achieved revenue of $696 million and an EBIT of $62.6 million, in line with guidance.
- Non-COVID revenue increased by 5.4% to $646.7 million, demonstrating strong performance in core operations.
- The company declared a final fully franked dividend of $0.09 per share, totaling $0.12 per share for the full financial year, representing a 4.6% yield.
- Operational improvements and a focus on efficiency led to a 101% operating cash flow conversion from EBITDA.
- The company announced a 12-month on-market share buyback program of up to 20 million shares, aimed at enhancing shareholder value.
- The company faced significant challenges due to the transition from pandemic to endemic COVID-19, resulting in a 59% decline in COVID revenue.
- Labor costs were impacted by a 5.75% Modern Award increase, higher workers' compensation rates, and a superannuation increase.
- Rent expenses increased by 4% due to inflationary pressures, affecting overall cost management.
- The company incurred over $9 million in nonrecurring costs, primarily related to the Healius transaction.
- Despite improvements, the market has not yet returned to predictable growth, and volumes remain difficult to forecast.
Good morning, everyone. On behalf of ACL, I'd like to start by acknowledging the Traditional Custodians of the land on which we meet today. I'm based in Sydney on the lands of the Wangal People, one of the 29 tribes of the Eora Nation. Melinda and Lana are joining us from the lands of the Wurundjeri and Bunurong Peoples of the Kulin Nation.
We acknowledge the Traditional Custodians of country throughout Australia and the places from which our participants join us on this webinar and their connections to land, sea and community. We pay our respects to their Elders past and present and extend that respect to Aboriginal and Torres Strait Islander peoples here today.
Welcome to the investor webinar for Australian clinical labs. FY24 financial results. My name is Eleanor Padman. I am the company secretary ACL. I'm joined today on this webinar by our Group CEO and Executive Director, Melinda McGrath; and our Deputy CFO, Lana Hudson; and our National Marketing Director, Joe Geran.
Today's webinar will run for
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
